Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Development and validation of a high performance liquid chromatography method to determine nevirapine in plasma in a resource-limited setting.

Makita-Chingombe F, Ocque AJ, DiFrancesco R, Maponga C, Muzambi F, Monera-Penduka TG, Mudzviti T, Mtisi TJ, Morse GD.

Afr J Lab Med. 2019 May 16;8(1):880. doi: 10.4102/ajlm.v8i1.880. eCollection 2019.

2.

Tenofovir-associated kidney disease in Africans: a systematic review.

Mtisi TJ, Ndhlovu CE, Maponga CC, Morse GD.

AIDS Res Ther. 2019 Jun 6;16(1):12. doi: 10.1186/s12981-019-0227-1. Review.

3.

Development and validation of an assay to measure cannabidiol and Δ9-tetrahydrocannabinol in human EDTA plasma by UHPLC-MS/MS.

Ocque AJ, Hagler CE, DiFrancesco R, Lombardo J, Morse GD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Apr 1;1112:56-60. doi: 10.1016/j.jchromb.2019.03.002. Epub 2019 Mar 3.

PMID:
30852450
4.

Sources of Variability and Accuracy of Performance Assessment in the Clinical Pharmacology Quality Assurance Proficiency Testing Program for Antiretrovirals.

Browne RW, Rosenkranz SL, Wang Y, Taylor CR, DiFrancesco R, Morse GD.

Ther Drug Monit. 2019 Aug;41(4):452-458. doi: 10.1097/FTD.0000000000000612.

PMID:
30829950
5.

In vitro Pharmacokinetic Cell Culture System that Simulates Physiologic Drug and Nanoparticle Exposure to Macrophages.

Kutscher HL, Morse GD, Prasad PN, Reynolds JL.

Pharm Res. 2019 Feb 1;36(3):44. doi: 10.1007/s11095-019-2576-9.

6.

Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Acosta EP, Mager DE, Morse GD; AIDS Clinical Trials Group Study A5202 Team.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e01638-18. doi: 10.1128/AAC.01638-18. Print 2019 Apr.

PMID:
30642925
7.

Mycobacterium Tuberculosis and Interactions with the Host Immune System: Opportunities for Nanoparticle Based Immunotherapeutics and Vaccines.

Bekale RB, Du Plessis SM, Hsu NJ, Sharma JR, Sampson SL, Jacobs M, Meyer M, Morse GD, Dube A.

Pharm Res. 2018 Nov 8;36(1):8. doi: 10.1007/s11095-018-2528-9. Review.

8.

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.

Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD.

Pharmacogenet Genomics. 2018 Jul;28(7):179-187. doi: 10.1097/FPC.0000000000000341.

9.

Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.

Ocque AJ, Hagler CE, Morse GD, Letendre SL, Ma Q.

J Pharm Biomed Anal. 2018 Jul 15;156:163-169. doi: 10.1016/j.jpba.2018.04.035. Epub 2018 Apr 23.

10.

Strategic establishment of an International Pharmacology Specialty Laboratory in a resource-limited setting.

Mtisi TJ, Maponga C, Monera-Penduka TG, Mudzviti T, Chagwena D, Makita-Chingombe F, DiFranchesco R, Morse GD.

Afr J Lab Med. 2018 Feb 12;7(1):659. doi: 10.4102/ajlm.v7i1.659. eCollection 2018.

11.

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage.

Talal AH, Dumas EO, Bauer B, Rejman RM, Ocque A, Morse GD, Lucic D, Cloherty GA, King J, Zha J, Zhang H, Cohen DE, Shulman N, Pawlotsky JM, Hézode C.

J Infect Dis. 2018 Jan 17;217(3):474-482. doi: 10.1093/infdis/jix495.

12.

Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.

Venuto CS, Lim J, Messing S, Hunt PW, McComsey GA, Morse GD.

Antivir Ther. 2018;23(4):345-351. doi: 10.3851/IMP3209.

13.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD.

Ther Drug Monit. 2017 Dec;39(6):596-603. doi: 10.1097/FTD.0000000000000443.

14.

Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s.

Kiser JJ, Lu D, Rosenkranz SL, Morse GD, DiFrancesco R, Sherman KE, Butt AA; ACTG A5309s study team.

Drugs R D. 2017 Dec;17(4):557-567. doi: 10.1007/s40268-017-0205-9.

15.

Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population.

Adedeji WA, Igbinoba SI, Fakeye TO, Oladosu IA, Fehintola FA, Ma Q, Morse GD.

Expert Rev Clin Pharmacol. 2017 Oct;10(10):1145-1152. doi: 10.1080/17512433.2017.1362979. Epub 2017 Aug 30.

16.

Mentoring Interventions for Underrepresented Scholars in Biomedical and Behavioral Sciences: Effects on Quality of Mentoring Interactions and Discussions.

Lewis V, Martina CA, McDermott MP, Chaudron L, Trief PM, LaGuardia JG, Sharp D, Goodman SR, Morse GD, Ryan RM.

CBE Life Sci Educ. 2017 Fall;16(3). pii: ar44. doi: 10.1187/cbe.16-07-0215.

17.

Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s.

Gupta SK, Yeh E, Kitch DW, Brown TT, Venuto CS, Morse GD, Ha B, Melbourne K, McComsey GA.

J Antimicrob Chemother. 2017 Jul 1;72(7):2042-2048. doi: 10.1093/jac/dkx076.

18.

Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates.

Ocque AJ, Hagler CE, DiFrancesco R, Morse GD, Talal AH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 1;1052:103-109. doi: 10.1016/j.jchromb.2017.03.020. Epub 2017 Mar 24.

19.

Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study.

Monera-Penduka TG, Maponga CC, Wolfe AR, Wiesner L, Morse GD, Nhachi CF.

AIDS Res Ther. 2017 Mar 14;14:12. doi: 10.1186/s12981-017-0140-4. eCollection 2017.

20.

Paritaprevir and Ritonavir Liver Concentrations in Rats as Assessed by Different Liver Sampling Techniques.

Venuto CS, Markatou M, Woolwine-Cunningham Y, Furlage R, Ocque AJ, DiFrancesco R, Dumas EO, Wallace PK, Morse GD, Talal AH.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02283-16. doi: 10.1128/AAC.02283-16. Print 2017 May.

21.

Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Bednasz CJ, Venuto CS, Ma Q, Morse GD.

Clin Pharmacol Drug Dev. 2017 Mar;6(2):135-139. doi: 10.1002/cpdd.313. Review.

22.

Capacity for ethical and regulatory review of herbal trials in developing countries: a case study of Moringa oleifera research in HIV-infected patients.

Monera-Penduka TG, Maponga CC, Morse GD, Nhachi CFB.

J Pharm Policy Pract. 2017 Feb 20;10:9. doi: 10.1186/s40545-017-0099-5. eCollection 2017.

23.

Quality and labeling information of Moringa oleifera products marketed for HIV-infected people in Zimbabwe.

Monera-Penduka TG, Jani ZT, Maponga CC, Mudzengi J, Morse GD, Nhachi CF.

J Public Health Afr. 2016 Dec 31;7(2):84-88. doi: 10.4081/jphia.2016.618.

24.

Emerging Nanomedicine Approaches to Targeting HIV-1 and Antiretroviral Therapy.

Kutscher HL, Prasad PN, Morse GD, Reynolds JL.

Future Virol. 2016 Feb;11(2):101-104. doi: 10.2217/fvl.15.114. Epub 2016 Feb 3. No abstract available.

25.

Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.

Verma A, Bradford Y, Verma SS, Pendergrass SA, Daar ES, Venuto C, Morse GD, Ritchie MD, Haas DW.

Pharmacogenet Genomics. 2017 Mar;27(3):101-111. doi: 10.1097/FPC.0000000000000263.

26.

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals.

Nwogu JN, Ma Q, Babalola CP, Adedeji WA, Morse GD, Taiwo B.

AIDS Res Treat. 2016;2016:2587094. Epub 2016 Sep 29. Review.

27.

Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver.

Ocque AJ, Hagler CE, Difrancesco R, Woolwine-Cunningham Y, Bednasz CJ, Morse GD, Talal AH.

Bioanalysis. 2016 Jul;8(13):1353-63. doi: 10.4155/bio-2016-0040. Epub 2016 Jun 9.

28.

Poly(lactic-co-glycolic) Acid-Chitosan Dual Loaded Nanoparticles for Antiretroviral Nanoformulations.

Makita-Chingombe F, Kutscher HL, DiTursi SL, Morse GD, Maponga CC.

J Drug Deliv. 2016;2016:3810175. doi: 10.1155/2016/3810175. Epub 2016 Apr 17.

29.

Editorial Commentary: Malaria and HIV/AIDS Interaction in Ugandan Children.

Fehintola FA, Adedeji WA, Morse GD.

Clin Infect Dis. 2016 Aug 1;63(3):423-4. doi: 10.1093/cid/ciw294. Epub 2016 May 3. No abstract available.

PMID:
27143664
30.

Recent advances in management of the HIV/HCV coinfected patient.

Bednasz CJ, Sawyer JR, Martinez A, Rose PG, Sithole SS, Hamilton HR, Kaufman FS, Venuto CS, Ma Q, Talal A, Morse GD.

Future Virol. 2015;10(8):981-997.

31.

Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.

Bednasz C, Luque AE, Zingman BS, Fischl MA, Gripshover BM, Venuto CS, Gu J, Feng Z, DiFrancesco R, Morse GD, Ma Q.

Curr Vasc Pharmacol. 2016;14(3):280-7.

32.

A Randomized Controlled Trial of Mentoring Interventions for Underrepresented Minorities.

Lewis V, Martina CA, McDermott MP, Trief PM, Goodman SR, Morse GD, LaGuardia JG, Sharp D, Ryan RM.

Acad Med. 2016 Jul;91(7):994-1001. doi: 10.1097/ACM.0000000000001056.

33.

Macrophage Targeted Nanoparticles for Antiretroviral (ARV) Delivery.

Kutscher HL, Makita-Chingombe F, DiTursi S, Singh A, Dube A, Maponga CC, Morse GD, Reynolds JL.

J Pers Nanomed. 2015 Nov;1(2):40-48. Epub 2015 Nov 14.

34.

Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.

Rowe IA, Tully DC, Armstrong MJ, Parker R, Guo K, Barton D, Morse GD, Venuto CS, Ogilvie CB, Hedegaard DL, McKelvy JF, Wong-Staal F, Allen TM, Balfe P, McKeating JA, Mutimer DJ.

Liver Transpl. 2016 Mar;22(3):287-97. doi: 10.1002/lt.24349.

35.

Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.

Parikh S, Fehintola F, Huang L, Olson A, Adedeji WA, Darin KM, Morse GD, Murphy RL, Taiwo BO, Akinyinka OO, Adewole IF, Aweeka FT, Scarsi KK.

Antimicrob Agents Chemother. 2015 Dec;59(12):7852-6. doi: 10.1128/AAC.01153-15. Epub 2015 Sep 21.

36.

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE.

Pharmacogenet Genomics. 2015 Sep;25(9):450-61. doi: 10.1097/FPC.0000000000000156.

37.

Adding value to antiretroviral proficiency testing.

DiFrancesco R, Taylor CR, Rosenkranz SL, Tooley KM, Pande PG, Siminski SM, Jenny RW, Morse GD.

Bioanalysis. 2014 Oct;6(20):2721-32. doi: 10.4155/bio.14.139.

38.

Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.

Malvestutto CD, Ma Q, Morse GD, Underberg JA, Aberg JA.

J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):390-6. doi: 10.1097/QAI.0000000000000333.

39.

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD.

J Antimicrob Chemother. 2014 Dec;69(12):3300-10. doi: 10.1093/jac/dku303. Epub 2014 Aug 25.

40.

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH.

J Antimicrob Chemother. 2014 Aug;69(8):2175-82. doi: 10.1093/jac/dku110. Epub 2014 Apr 11.

41.

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.

Johnson DH, Venuto C, Ritchie MD, Morse GD, Daar ES, McLaren PJ, Haas DW.

Pharmacogenet Genomics. 2014 Apr;24(4):195-203. doi: 10.1097/FPC.0000000000000034.

42.

Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.

Scarsi KK, Fehintola FA, Ma Q, Aweeka FT, Darin KM, Morse GD, Akinola IT, Adedeji WA, Lindegardh N, Tarning J, Ojengbede O, Adewole IF, Taiwo B, Murphy RL, Akinyinka OO, Parikh S.

J Antimicrob Chemother. 2014 May;69(5):1370-6. doi: 10.1093/jac/dkt513. Epub 2014 Jan 19.

43.

Multimodal nanoparticles that provide immunomodulation and intracellular drug delivery for infectious diseases.

Dube A, Reynolds JL, Law WC, Maponga CC, Prasad PN, Morse GD.

Nanomedicine. 2014 May;10(4):831-8. doi: 10.1016/j.nano.2013.11.012. Epub 2013 Dec 10.

PMID:
24333593
44.

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; AIDS Clinical Trials Group 5202 Study Team.

Clin Infect Dis. 2014 Feb;58(4):555-63. doi: 10.1093/cid/cit747. Epub 2013 Nov 18.

45.

Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism.

McCance-Katz EF, Gruber VA, Beatty G, Lum P, Ma Q, DiFrancesco R, Hochreiter J, Wallace PK, Faiman MD, Morse GD.

Am J Addict. 2014 Mar-Apr;23(2):137-44. doi: 10.1111/j.1521-0391.2013.12081.x. Epub 2013 Oct 11.

46.

Clinical pharmacology quality assurance program: models for longitudinal analysis of antiretroviral proficiency testing for international laboratories.

DiFrancesco R, Rosenkranz SL, Taylor CR, Pande PG, Siminski SM, Jenny RW, Morse GD.

Ther Drug Monit. 2013 Oct;35(5):631-42. doi: 10.1097/FTD.0b013e31828f5088.

47.

Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study.

Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, Amorosa V, Bhattacharya D, Coughlin K, Wong-Staal F, Glesby MJ; AIDS Clinical Trials Group A5277 Protocol Team.

J Infect Dis. 2014 Mar 1;209(5):658-67. doi: 10.1093/infdis/jit503. Epub 2013 Sep 16.

48.

Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients.

Mikula JM, Hsiao CB, Sawyer JR, Ma Q, Morse GD.

AIDS Res Treat. 2013;2013:687176. doi: 10.1155/2013/687176. Epub 2013 Jul 17.

49.

Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.

Ma Q, Gelbard HA, Maggirwar SB, Dewhurst S, Gendelman HE, Peterson DR, DiFrancesco R, Hochreiter JS, Morse GD, Schifitto G.

J Neurovirol. 2013 Jun;19(3):254-60. doi: 10.1007/s13365-013-0172-z. Epub 2013 Jun 5.

50.

Clinical pharmacology quality assurance for HIV and related infectious diseases research.

DiFrancesco R, Tooley K, Rosenkranz SL, Siminski S, Taylor CR, Pande P, Morse GD.

Clin Pharmacol Ther. 2013 Jun;93(6):479-82. doi: 10.1038/clpt.2013.62. Epub 2013 Mar 26. No abstract available.

Supplemental Content

Loading ...
Support Center